Track topics on Twitter Track topics that are important to you
On the 28th October 2008 Pfizer announced its new anti-infective partnership with the Eskitis Institute at Griffith University. In this interview Fintan Walton talks with Stuart Newman, the institute’s Business Manager, about what this collaboration means for them. Dr Newman explains why the Eskitis Institute has succeeded in the world of natural products where so many have struggled and how they are using their capabilities from 14 years of experience within this field to drive products forward into pharmaceutical pipelines.
Original Article: New Pharma Partner for Eskitis InstituteNEXT ARTICLE
Pfizer is a global pharmaceutical company, the largest in world based on annual sales. In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...